Vor Biopharma CMO reports initial stock holdings
Vor Biopharma Inc. filed an initial ownership report for Chief Medical Officer Jeremy Brett Sokolove.
Rhea-AI Filing Summary
Vor Biopharma Inc. filed an initial ownership report for Chief Medical Officer Jeremy Brett Sokolove. He holds employee stock options to acquire 130,100 shares of common stock at an exercise price of $8.18 per share, expiring on October 31, 2035, with vesting beginning November 1, 2026 and continuing over the following three years. He also reports direct ownership of 27,900 shares of common stock, alongside restricted stock units that vest starting November 1, 2026, with remaining units vesting quarterly over three years, all subject to his continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Sokolove Jeremy Brett
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 130,100 contracts (Direct);
Common Stock — 27,900 shares (Direct)
Footnotes (3)
- F1. Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. 1/4th of the RSUs shall vest on November 1, 2026, with the remainder vesting in substantially equal quarterly installments over the following 3 years, in each case subject to the Reporting Person's continued service as of each such vesting date.
- F2. 1/4th of the shares underlying the option vest on November 1, 2026, with the remainder vesting in substantially equal monthly installments over the following 3 years, in each case subject to the Reporting Person's continued service as of each such vesting date.
- F3. On December 5, 2025, the Issuer's Board of Directors approved a stock option award repricing, pursuant to which the exercise price was reduced to $8.18. Under the terms of the stock option award repricing, the exercise price of this award will revert to $24.11 if the option is exercised prior to the earliest of (i) December 5, 2027; (ii) a Change in Control during the option holder's Continuous Service (each as defined in the Issuer's 2023 Inducement Plan); and (iii) 30 days prior to the option's original expiration date.
Key Figures
Stock options underlying shares: 130,100 shares
Option exercise price: $8.18 per share
Option expiration date: October 31, 2035
+3 more
6 metrics
Stock options underlying shares
130,100 shares
Employee stock option to buy common stock
Option exercise price
$8.18 per share
Employee stock option exercise price after repricing
Option expiration date
October 31, 2035
Employee stock option expiration
Direct common shares held
27,900 shares
Common stock directly owned by CMO
Initial vesting date for options
November 1, 2026
One quarter of option shares vest
Initial RSU vesting date
November 1, 2026
One quarter of RSUs vest
Key Terms
restricted stock units ("RSUs"), exercise price, stock option award repricing, Change in Control, +1 more
5 terms
restricted stock units ("RSUs") financial
"Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
exercise price financial
"pursuant to which the exercise price was reduced to $8.18. Under the terms of the stock option award repricing"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
stock option award repricing financial
"the Issuer's Board of Directors approved a stock option award repricing, pursuant to which the exercise price was reduced"
Change in Control financial
"the earliest of (i) December 5, 2027; (ii) a Change in Control during the option holder's Continuous Service"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
Continuous Service financial
"a Change in Control during the option holder's Continuous Service (each as defined in the Issuer's 2023 Inducement Plan)"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Vor Biopharma (VOR) Form 3 filing show for Jeremy Sokolove?
The Form 3 shows Chief Medical Officer Jeremy Brett Sokolove’s initial ownership in Vor Biopharma, including stock options and common shares. It outlines his equity-based incentives and how they vest over time, tied to his continued service with the company.
How many stock options does Vor Biopharma’s CMO report on the Form 3?
Jeremy Brett Sokolove reports employee stock options over 130,100 shares of Vor Biopharma common stock. These options carry an exercise price of $8.18 per share and expire on October 31, 2035, subject to a multi-year vesting schedule based on continued service.
What common stock holdings does the Vor Biopharma CMO report?
The filing shows Jeremy Brett Sokolove directly holding 27,900 shares of Vor Biopharma common stock. This position is in addition to his employee stock options and restricted stock units, providing him with an immediate equity stake alongside longer-term incentive awards.
How do Jeremy Sokolove’s stock options at Vor Biopharma vest over time?
According to the footnotes, one quarter of the option shares vest on November 1, 2026. The remaining shares then vest in substantially equal monthly installments over the following three years, contingent on his continued service with Vor Biopharma at each vesting date.
What are the key terms of the restricted stock units reported in the Vor Biopharma Form 3?
The restricted stock units represent a right to receive common shares, with one quarter vesting on November 1, 2026. The balance vests in substantially equal quarterly installments over the next three years, conditioned on Jeremy Brett Sokolove’s continued service at each vesting point.
Was there a repricing of Vor Biopharma stock options held by the CMO?
Yes. On December 5, 2025, Vor Biopharma’s board approved a repricing that reduced the option exercise price to $8.18. This lower exercise price can revert to $24.11 if the option is exercised before certain specified dates or corporate events defined in the 2023 Inducement Plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
